Fortrea Holdings Inc.（纳斯达克代码：FTRE）首席运营官Mark A. Morais近期出售了该公司价值4,980美元的普通股。这家市值约8.95亿美元的临床研究机构的股票交易发生在2025年3月12日，平均售价为9.98美元，接近该股52周低点9.55美元。根据 InvestingPro ...

根据提交给证券交易委员会的文件显示，Fortrea Holdings Inc.（NASDAQ:FTRE）首席财务官Jill G. McConnell近期出售了公司股票。3月12日，McConnell以平均价格$9.98出售了643股，总价值约$6,417。该交易发生之际，Fortrea股票接近其52周低点$9.55，过去一年下跌超过74%。

NEW YORK CITY, NY / ACCESS Newswire / March 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

William Blair：重申Fortrea Holdings(FTRE.US)评级，由大市一致调整至大市一致评级。 Fortrea Holdings（FTRE.US）公司简介：Fortrea Holdings是一家后期合同研究组织 ...

Investing.com — Here is your Pro Recap of the biggest insider trades and institutional investor headlines you may have ...

Fortrea Holdings Inc. ( (FTRE)) has released its Q4 earnings. Here is a breakdown of the information Fortrea Holdings Inc. presented to its investors. Discover the Best Stocks and Maximize Your ...

NEW YORK, March 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Fortrea Holdings Inc. ("Fortrea" or the "Company") (NASDAQ: FTRE). Such investors are ...

Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions.

Fitch predicts a 7.3% decline in Fortrea’s revenues in 2025 and expects revenue growth to return in 2026 within the 3.0% to 4.0% range. The company’s inconsistent revenue growth and uncertain ...

Ladies and gentlemen, thank you for standing by, and welcome to Fortrea Fourth Quarter 2024 Earnings Conference Call. [Operator Instructions] Please be advised that today’s conference is being ...

Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions.